California awards UCLA $50 million to administer statewide prostate cancer treatment program

July 11, 2001

California Awards UCLA $50 Million to Administer Statewide Prostate Cancer Treatment Program Program slated to improve awareness, education and treatment for uninsured men

University and state officials announced today the establishment of a new statewide prostate cancer treatment program to help uninsured men with prostate cancer receive critical medical care. The initial three-year program, administered by UCLA, is funded with $50 million from the state of California. The new program is called IMPACT: Improving Access, Counseling and Treatment for Californians with Prostate Cancer.

The first three regional sites open today at UCLA Medical Center, the University of California at San Francisco and the University of California at Davis (located in Sacramento). Next year the University of California at Irvine and the University of California at San Diego will open, followed by additional sites around the state.

IMPACT will help men, regardless of age, who have no or limited health insurance, do not qualify for Medi-Cal, do not have Medicare and have incomes under 200 percent of the federal poverty level. Once fully operational, the new program aims to offer comprehensive treatment for prostate cancer to qualifying men. It is estimated that there are 3.5 million uninsured Californian men, from all ages up to 64. In addition to offering treatment, the new program is designed to increase education and promote awareness about the importance of timely, high quality prostate cancer treatment.

The UCLA Department of Urology will manage IMPACT and subcontract with the regional sites to coordinate care. The state department of health services will administer the funding and oversee the overall program.

"This is a major award for UCLA and the UC System," said Dr. Gerald S. Levey, UCLA's provost of medical sciences and dean of the school of medicine. "We are very pleased to administer this program that will help improve men's health in California."

"This is the largest program of its kind nationwide to address the public health issue of prostate cancer among lower-income, uninsured men," said Dr. Mark Litwin, program director and associate professor, UCLA Departments of Urology and Health Services and researcher with UCLA's Jonsson Cancer Center, "We hope that the program will become a model for other states to follow."

According to Litwin, men diagnosed with prostate cancer typically require a significant amount of information and advice in selecting treatment choices, yet few materials or strategies have targeted those from disadvantaged backgrounds. A special health education team will design outreach strategies that address the cultural, ethnic and low-literacy issues often found in underserved communities in California. The team will also create key materials and address the psychosocial issues of working with uninsured and other at-risk individuals.

Another team will implement evaluation tools to measure the quality of care and assess outcomes. According to Litwin, this new system may help establish better methods to monitor the quality of care in other prostate cancer treatment programs nationwide.

Each regional center will offer patient care as well as work with local health departments and other community providers to establish a growing network of health facilities statewide that will help patients be evaluated and treated in their local communities.

"In California, a total of 21,180 new cases of prostate cancer were diagnosed in 1999," said Dr. Jean B. deKernion, Chair, UCLA Department of Urology and the Clark Urological Center. "Timely treatment is critical with prostate cancer and this program will help us reach more men in California than ever before."
For more information about the program, please call 1-800-409-UCLA or visit the website:

Additional Contacts:
Kim Irwin,
Marisa Osorio,

University of California - Los Angeles

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to